A Study of ISIS 2922 in the Treatment of Advanced Cytomegalovirus Retinitis
A Randomized Comparison of Two Dosage Schedules of Intravitreal ISIS 2922 for Patients With Advanced Cytomegalovirus Retinitis
Sponsor: Ionis Pharmaceuticals, Inc.
This NA trial investigates Cytomegalovirus Retinitis and HIV Infections and is currently completed. Ionis Pharmaceuticals, Inc. leads this study, which shows 6 recorded versions since 2026 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed NA
-
Sep 2024 — Sep 2025 [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jan 2021 — Jul 2024 [monthly]
Completed NA
-
Jun 2018 — Jan 2021 [monthly]
Completed NA
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Ionis Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Atlanta, United States, Charlotte, United States, Chicago, United States, Durham, United States, Fort Lauderdale, United States, Houston, United States, Indianapolis, United States, Los Angeles, United States, New York, United States, Pasadena, United States and 4 more location s